Overview of Itrafungol

Quick Facts

Property	Description
Active ingredient	Itraconazole
Form	Oral solution
Pharmacological class	Systemic antifungal drug (Triazole)
General purpose	To stop the growth of fungal infections
Origin	Synthetic derivative

What is Itrafungol? Definition and Classification

Itrafungol is a prescription-only veterinary medicine classified as a systemic antifungal drug within the group of triazole derivatives. Its primary purpose is to act as a broad-spectrum agent designed to halt the proliferation of various fungal pathogens. The medicine is based on the active compound Itraconazole, which is a synthetic compound. Itraconazole is a potent antifungal agent, effective against a wide range of clinically relevant fungi; the medicine is used for addressing infections caused by diverse fungal species.

Composition, Form, and Delivery System

The active ingredient in Itrafungol is Itraconazole, typically present at a concentration of 10 mg/mL. The drug is formulated specifically as an oral solution, a characteristic differentiating it from other Itraconazole products often supplied in capsule form. Itrafungol is a single-ingredient product, and due to the inherent lipophilic nature of Itraconazole, the formulation requires a specialized liquid base/vehicle containing solubilizing agents like hydroxypropyl-beta-cyclodextrin. This solution format is designed for precision dosing in specific patient groups, allowing the medicine, administered via the oral route of administration, to be absorbed for systemic distribution throughout the affected tissues.

Core Mechanism Principle: Understanding the Fungistatic Effect

The core principle behind the action of Itraconazole is its fungistatic effect, which means it impedes fungal growth and replication without necessarily causing rapid cell death. Itraconazole achieves this by interfering with the fungus’s ability to produce ergosterol, a key structural material that is vital for maintaining the integrity and stability of the fungal cell membrane. By blocking the synthesis of this essential component, the drug impairs the fungus structurally and functionally, which assists the body’s immune system in resolving the established infection.

What side effects are possible with Itrafungol?

Possible Side Effects and Safety Information

The safety profile for Itrafungol is primarily characterized by adverse reactions affecting the gastrointestinal tract and the liver, as documented in official regulatory labeling. These effects are formally classified by frequency according to standards set by regulatory authorities.

Frequency-Classified Adverse Reactions

Adverse reactions are grouped into categories based on their observed occurrence rates:

Common effects (those potentially affecting up to 1 in 10 individuals) include vomiting, diarrhea, anorexia (lack of appetite), and elevated liver enzymes.
Uncommon effects (those potentially affecting up to 1 in 100 individuals) involve conditions such as lethargy, depression, weight loss, and skin/hair issues like alopecia (hair loss) and pruritus (itching).

Organ System and Serious Adverse Reactions

Reactions are classified into System-Organ Classes. Adverse events related to the Hepatobiliary System are the most serious concern. While the elevation of liver enzymes is often transient and reversible upon cessation of therapy, regulatory documents note the potential for hepatic dysfunction, including rare reports of fatal hepatic failure. Gastrointestinal issues are often noted to be observed early in the course of treatment.

Population-Specific Safety Constraints

Official labeling defines specific restrictions for use based on population risk:

The medicine is contraindicated in individuals with known hypersensitivity to the active substance.
It is contraindicated in individuals with severe liver impairment due to the drug's effect on hepatic function.
Use is contraindicated in pregnant or lactating individuals due to documented risks of embryotoxicity and excretion into milk.
Safety has not been established for use in very young, small patients.

Overdose and Emergency Response

Overdose Manifestations and Severe Risks

Official regulatory labeling indicates that specific data on the acute signs and symptoms following an overdose of Itrafungol are not available. However, due to the drug's known systemic profile, the primary concerns associated with excessive exposure relate to potential life-threatening toxic effects. These include the risk of developing fatal acute liver failure and serious cardiovascular complications, such as life-threatening cardiac dysrhythmias or the exacerbation of congestive heart failure due to decreased cardiac contractility.

When to Seek Immediate Medical Help

Immediate medical attention is required in the event of suspected overdose or if signs of severe systemic toxicity occur during treatment. Regulatory documents mandate the discontinuation of treatment and urgent performance of liver function testing if clinical manifestations consistent with liver disease (e.g., unusual fatigue, dark urine) or heart failure are observed.

Management and Procedures

No specific antidote is known or available for Itraconazole overdose. Management must therefore be strictly supportive and symptomatic. Procedures officially described in the event of acute ingestion include the implementation of general supportive measures, the administration of activated charcoal, and performing gastric lavage if the ingestion occurred within the first hour. Due to the active substance's high protein binding, the regulatory literature notes that Itraconazole is not removable by hemodialysis.

Population Considerations

Caution is advised concerning the overdose risk in individuals with pre-existing hepatic impairment or renal impairment, as altered drug exposure and prolonged elimination have been documented in these populations.

Therapeutic Uses of Itrafungol

What Itrafungol Treats: Main Uses and Benefits

Itrafungol, a systemic antifungal agent, is used to provide systemic support in managing fungal conditions, which generally helps ease the overall symptom burden. It is applied across two primary symptomatic domains.

Treating Dermatological Symptoms and Ringworm

This domain helps address integumentary manifestations that may interfere with a patient's comfort. Itrafungol is primarily indicated for the treatment of Dermatophytosis (ringworm) caused by Microsporum canis in cats. The medication is used to support the resolution of clinical lesions, which include hair loss, scaling, and crusting. It contributes to supporting skin health and assists with managing the underlying fungal presence.

Quick Fact: Relief for Fungal Skin Symptoms The therapy is relevant for conditions presenting with disruptive signs like alopecia, crusting, and scaling, and is applied in addressing these challenging skin manifestations.

Managing Severe and Disseminated Fungal Illnesses

While its common indication is specific to feline Dermatophytosis, the active ingredient, itraconazole, is commonly used in veterinary medicine for more challenging clinical contexts. These include systemic mycoses such as Blastomycosis and Histoplasmosis in dogs, and certain presentations of Cryptococcosis. It is applied in these contexts to provide systemic therapeutic support in addressing the internal spread of the pathogen. This medication supports the patient during difficult episodes by easing the overall symptom load, and assists with managing severe internal symptoms related to organ-specific functional stress, which may assist with maintaining functional stability in conditions marked by increased physiological stress.

Regulatory References

FDA Freedom of Information Summary

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

The eligibility for Itrafungol (Itraconazole oral solution) is strictly governed by regulatory documentation and applies only to cats for the treatment of Microsporum canis dermatophytosis.

Absolute Contraindications

The medicine must not be administered to specific populations, as defined by official labeling:

Species: Any species other than cats is contraindicated.
Hypersensitivity: Cats with known allergy to itraconazole or any of the product’s components.
Organ Impairment: Cats with existing impaired liver function or impaired kidney function.
Reproductive Status: Pregnant queens and lactating queens (nursing cats) are contraindicated due to the risk of malformations and foetal resorptions observed in laboratory studies.

Conditional Use and Restrictions

Certain eligible cats require close monitoring and caution during treatment:

Heart Disease: Cats suffering from heart disease must be carefully monitored, and treatment should be withdrawn if clinical signs of the heart condition deteriorate.
Comorbidities: Use requires caution in cats with renal dysfunction and in those with existing impaired liver function (where treatment must be discontinued if signs of liver dysfunction develop).
Age: No specific age restriction is documented for kittens or older adult cats, but careful dosing is required for kittens.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Itrafungol (Itraconazole) is defined by its documented effects on major metabolic pathways. Official regulatory documents classify certain combinations based on the risk of altered drug exposure.

Contraindicated Combinations

Co-administration is officially contraindicated with numerous substances that are sensitive CYP3A4 substrates, including specific antiarrhythmics, statins (HMG CoA-Reductase Inhibitors), and ergot alkaloids. This restriction is necessary because Itraconazole acts as a potent inhibitor of the CYP3A4 enzyme system, which can cause a significant increase in the plasma concentration of the co-administered drugs and may lead to serious adverse effects like QT prolongation. Antipsychotics and certain sedatives are also listed in this prohibited category.

Exposure Modification and Other Interactions

Itraconazole's inhibition of the P-glycoprotein (P-gp) transporter can similarly increase the exposure of P-gp substrate drugs. Conversely, co-administration with strong CYP3A4 inducers (e.g., rifampicin, phenytoin) is documented to reduce the plasma concentration of Itraconazole itself, potentially lowering its efficacy. The label notes that calcium channel blockers may have additive negative inotropic effects with Itraconazole, increasing the risk of congestive heart failure. The absorption of the Itraconazole Oral Solution is officially documented as being increased under fasted conditions.

Population-Specific Notes

Interaction severity for certain co-administered drugs is officially heightened in subjects with varying degrees of renal or hepatic impairment.

Mechanism of Action

The mechanism of action for the active ingredient, Itraconazole, is defined by its selective interference with fungal cell biology. The molecular process begins with Itraconazole acting as a reversible inhibitor of the fungal enzyme Cytochrome P450 14alpha-demethylase (CYP51).

This critical inhibition arrests a primary metabolic step within the ergosterol biosynthesis pathway. The resulting mechanistic cascade causes a simultaneous dual physiological consequence for the fungus: depletion of the essential membrane stabilizer ergosterol and the toxic accumulation of methylated sterol precursors. The resulting loss of cell membrane fluidity and structural integrity leads to the primary physiological effect—a fungistatic state. This mechanism limits the fungal pathogen's ability to replicate and proliferate, resulting in a population of structurally and metabolically compromised cells.

Dosage and Administration Information

How to Use Itrafungol

The administration of Itrafungol Oral Solution follows a precise, intermittent cyclic regimen. The product is administered via the oral route using the enclosed graduated dosing syringe designed for accurate measurement. The dosing schedule involves a daily dose of 5 mg of itraconazole per kilogram of body weight (equivalent to 0.5 mL of the 10 mg/mL solution). This dosage is administered once daily.

The overall treatment course is defined by a structured cycle pattern rather than continuous use. The regimen consists of three alternating treatment periods, each lasting 7 consecutive days. Each 7-day treatment period is followed by a 7-day period without administration. This pattern establishes a total course duration spanning five weeks, encompassing three treated weeks and two untreated weeks.

Specific procedural instructions are provided to support proper usage and systemic absorption. The solution is administered between meals (without food). The graduated syringe must be used, and the bottle must remain upright when the dose is drawn. Instructions also cover precision for low-weight patients: kittens weighing less than 0.5 kg require the use of a 1 mL syringe for accurate measurement. Furthermore, if a fungal culture remains positive four weeks after the completion of the five-week course, the regimen may be repeated once.

Recent Clinical Evidence

Research Evidence Overview

Itrafungol is an oral solution containing itraconazole, a triazole antifungal agent. Clinical research has primarily focused on its use for treating dermatophytosis, or fungal skin infections, caused by organisms such as Microsporum canis.

Studies have assessed the effects of this drug using alternating-week pulse therapy regimens. These investigations track outcomes by evaluating changes in both clinical symptoms (e.g., skin lesions, hair condition) and mycological cure (defined as the absence of fungal growth in cultures). Research has also included comparisons to untreated control groups and other antifungal agents.

Clinical Findings and Symptom Management

Clinical trials have explored the relationship between the use of the itraconazole solution and the resolution of fungal infections. Researchers reported that subjects receiving treatment showed significant improvements in both clinical cure rates and the time taken to achieve mycological cure when compared to controls. This compound's tendency to bind to keratin and persist in hair and skin tissues has been a focus of research concerning its effectiveness in pulse-dosing schedules.

Safety Profile and Ongoing Research

Research evaluating the safety profile has noted common adverse events, which are generally mild and transient, primarily involving the gastrointestinal tract (e.g., vomiting, diarrhea, decreased appetite). Liver involvement, indicated by elevated liver enzymes, has also been observed in studies.

The long-term suitability of this drug continues to be an area of research, particularly concerning its use in subjects with pre-existing conditions like liver or heart disease. Researchers emphasize the importance of monitoring organ function during treatment periods, which aligns with guidance for other systemically active triazole antifungals.

How should Itrafungol be stored and disposed of?

Storage and Disposal of Itrafungol (Itraconazole Oral Solution)

Official regulatory documents specify mandatory conditions for storing Itrafungol to ensure product stability and safety.

Storage Requirements

The solution must be stored at controlled room temperature, generally defined as between 15 C and 25 C, and must not be stored above 25 C. The bottle must be kept tightly closed and remain in its outer carton.

Stability Constraint	Condition
Shelf-Life After Opening	Use or discard remaining solution within 5 weeks.

Protection and Disposal

The medicine must be kept out of the reach and sight of children and in a secure location away from pets to prevent accidental ingestion. Any unused or expired product and related waste material must be disposed of in accordance with national requirements for pharmaceutical waste and must not be put into household refuse or wastewater.

Itrafungol